ANPDFSep 212 min readA New Hope for NP-C Families: Introducing MiplyffaNew Hope for NP-C Families: Miplyffa, the first FDA-approved treatment for NPC, offers a promising future for our loved ones. Stay informed!
ANPDFAug 71 min readZevra Therapeutics Media Release | August 2, 2024FDA Advisory Committee Votes Favourably that the Data Support Arimoclomol as Effective Treatment for Patients with NP-C
ANPDFMar 51 min readZevra Therapeutics Media Release | March 4, 2024Zevra Therapeutics Provides FDA Update On The PDUFA Action Date For Arimoclomol As A Treatment For Niemann-Pick Disease Type C Read the...
ANPDFJan 101 min readZevra Therapeutics Media Release | January 8, 2024Zevra Therapeutics Receives FDA Acceptance Of Resubmission Of NDA For Arimoclomol As A Treatment For Niemann-Pick Disease Type C Read the...
ANPDFDec 28, 20231 min readZevra Therapeutics Media Release | December 27, 2023Zevra Therapeutics Announces Resubmission Of Arimoclomol New Drug Application To The U.S. Food And Drug Administration Read the full...
ANPDFNov 21, 20231 min readZevra Therapeutics Media Release | November 20, 2023Zevra announces the completion of its acquisition of Acer Therapeutics. Zevra states they are committed to the arimoclomol expanded...
